Literature DB >> 1475010

Long-term failure of compensatory growth in rats following acute neonatal passive immunization against growth hormone-releasing hormone.

W B Wehrenberg1, D M Voltz, S G Cella, E E Müller, R C Gaillard.   

Abstract

Interruption of hypothalamic growth hormone-releasing hormone (GHRH) secretion by administration of antiserum against GHRH (GHRH-ab) decreases growth hormone (GH) secretion and inhibits growth in rats. The present study was undertaken to investigate whether there is a period of accelerated or catch-up growth following a period of growth arrest induced by GHRH-ab treatment. Neonatal male and female rats were injected daily on days 1-14 of age. Animals received normal rabbit serum (NRS) or GHRH-ab subcutaneously at a dose of 5 microliters/10 g body weight. Body weight, serving as an index of somatic growth, was monitored over the next 3 months. The increase in absolute body weight and growth velocity of GHRH-ab-treated rats, regardless of gender, was lower than the increase of NRS-treated animals. Significant decreases were observed by day 13 of age in the female rats and day 17 in the male rats. The percent differences and absolute difference in weight between the two treatment groups clearly demonstrated that the GHRH-ab-treated rats did not demonstrate any period of catch-up growth. A second group of animals was treated in a similar fashion to evaluate serum GH concentrations at three months of age. Pulsatile GH secretion, as assessed by peak frequency and amplitude, was normal in all of the rats, suggesting that the failure of catch-up growth in the GHRH-ab-treated animals was not due to decreased GH secretion.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1475010     DOI: 10.1159/000126268

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN: 0028-3835            Impact factor:   4.914


  1 in total

1.  Antagonism of endogenous growth hormone-releasing hormone (GHRH) leads to reduced proliferation and apoptosis in MDA231 breast cancer cells.

Authors:  Philip Zeitler; Gamini Siriwardana
Journal:  Endocrine       Date:  2002-06       Impact factor: 3.633

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.